Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions 
One Percent Rule Checklist For Safer Forex Trading Risk 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
NEW YORK, April 13, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased SCYNEXIS, Inc. (NASDAQ:SCYX) securities (1) pursuant and/or traceable to the Registration Statement and Prospectus issued in connection with the Company’s Initial Public Offering on or about May 2, 2014 and/or (2) between May 2, 2014 and March 2, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra/scynexis-inc?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (i) SCYNEXIS’s lead product SCY-078 posed substantial undisclosed health and safety risks; (ii) consequently, the Company had overstated the drug’s approval prospects and/or commercial viability; and (iii) as a result of the foregoing, SCYNEXIS’s public statements were materially false and misleading at all relevant times.
On March 2, 2017, SCYNEXIS announced that the U.S. Food and Drug Administration “informed the Company to hold the initiation of any new clinical studies with the intravenous (IV) formulation of SCY-078 until the FDA completes a review of all available pre-clinical and clinical data” of the formulation. The hold stems from “three mild-to-moderate thrombotic events in healthy volunteers” receiving the formulation.
If you suffered a loss in SCYNEXIS you have until May 8, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/scynexis-inc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
